Evidence map›Paper›PMID 31941968›Full record

ArticleScientific reports2020

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation.

Taha Elmetwali, Asmaa Salman, Wenbin Wei, Syed A Hussain, Lawrence S Young, Daniel H Palmer

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. CD8Science advances · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. CD40-CD40L in Neurological Disease.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Article
  10. Article
  11. (Im)maturity in Tumor Ecosystem.Frontiers in oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Taha ElmetwaliInstitute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK. elmetwaa@liverpool.ac.uk.
Asmaa SalmanInstitute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.
Wenbin WeiInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
Syed A HussainSheffield Academic Unit of Oncology Department of Oncology and Metabolism Medical School, University of Sheffield, Sheffield, S10 2 RX, UK.
Lawrence S YoungWarwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.
Daniel H PalmerInstitute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.
University of Liverpool · GBClatterbridge Cancer Centre NHS Foundation Trust · GBDurham University · GBUniversity of Sheffield · GBUniversity of Warwick · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In carcinomas, the nature of CD40 ligand shapes the outcome of CD40 ligation. To date, the consequences of membrane-bound CD40L (mCD40L) on its immune-stimulatory function are unknown. Here, we examined the impact of mCD40L versus soluble CD40L (sCD40L) on T24 bladder carcinoma gene expression profiling. Of 410 differentially expressed genes, 286 were upregulated and 124 downregulated by mCD40L versus sCD40L. Gene ontology enrichment analysis revealed immune-stimulatory function as the most significant enriched biological process affected by upregulated transcripts, while those downregulated were critical for cell growth and division. Furthermore, immature dendritic cells (iDC) responded to mCD40L with enhanced maturation and activation over sCD40L evidenced by higher expression levels of CD83, CD86, HLA-DR and CD54, increased secretion of IL12 and IL10 and higher tumour-antigen (TA) uptake capacity. Furthermore, autologus CD3+ T cells responded to TA-loaded mCD40L-activated DC with increased proliferation and cytotoxic response (CD107a and IFN-γ-producing CD3+ CD8+ T cells) to the tumour-loaded autologous PBMCs compared to sCD40L. Thus, these data indicate that mCD40L enhances the immunostimulatory capacity over sCD40L. Furthermore, the ability of mCD40L to also directly induce cell death in CD40-expressing carcinomas, subsequently releasing tumour-specific antigens into the tumour microenvironment highlights the potential for mCD40L as a multi-faceted anti-cancer immunotherapeutic.

Indexed as

Antigens, CDAntigens, NeoplasmApoptosisCD40 AntigensCD40 LigandCD83 AntigenCD8-Positive T-LymphocytesCell Line, TumorCell MembraneCell ProliferationDendritic CellsGene Expression Regulation, NeoplasticGenetic VectorsHumansImmunoglobulinsInterferon-gammaAntigens, CDAntigens, NeoplasmCD40 AntigensCD40 LigandCD83 AntigenImmunoglobulinsInterferon-gammaInterleukin-10Membrane Glycoproteins

Identifiers

PMID31941968
PMCPMC6962220
OpenAlexW2999154069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.